ReviewInternational journal of molecular sciences2024
Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Fertility-preserving treatment for endometrial atypical hyperplasia and endometrial cancer: a systematic review and meta-analysis.BMC women's health · 2026Pooled it
- The Efficacy of Pembrolizumab Immunotherapy in the Treatment of Endometrial Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Research progress of probiotics intervention on reconstruction of intestinal flora and improvement of quality of life in patients after endometrial cancer surgery.Frontiers in cellular and infection microbiology · 2025Pooled it
- Subtype-specific mechanisms of lipid metabolism in gynecological malignancies and novel targeted intervention strategies (Review).Oncology letters · 2026Review
- MRI-Based Radiomics Model for Predicting Eligibility for Conservative Management of Endometrial Cancer.Cancer medicine · 2026Article
- ATAD2 suppresses senescence and SASP via SIRT7-p53/p21 to drive progression and immune evasion in endometrial cancer.Clinical epigenetics · 2026Article
- Effect of the new FIGO 2023 staging system on stage distribution and adjuvant therapies in endometrial cancer: A retrospective cohort study.Turkish journal of obstetrics and gynecology · 2026Article
- Redefining the Treatment Landscape of Advanced Endometrial Cancer in the Era of Immunotherapy and Precision Oncology.Cancers · 2026Review
- Prognostic Value of p53 Status in Endometrial Cancer: Real-World Evidence from a Tertiary Center.Cancers · 2026Article
- Biomaterial-enabled multimodal therapy for endometrial cancer: Subtype-guided immuno-metabolic modulation and fertility-conscious regeneration.Materials today. Bio · 2026Article
- When Immunophenotype Is Not Identity: A Clinicopathological Review of Neuroendocrine Differentiation in Tumors of the Female Genital Tract.Diagnostics (Basel, Switzerland) · 2026Review
- From Epigenetic Dysregulation to Therapeutic Reprogramming in Endometrial Cancer: A State-Response Framework for Treatment Resistance.International journal of molecular sciences · 2026Review
- Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Survival and Safety Outcomes of Three-Cycle Adjuvant Chemotherapy in Intermediate-Risk Endometrial Cancer.Cancers · 2026Article
- Transcriptomic subtypes in high-grade serous ovarian cancer are driven by tumor cellular composition.bioRxiv : the preprint server for biology · 2026Article
- MLH1 promoter methylation-induced dMMR/MSS in endometrial cancer: case report.Discover oncology · 2026Article
- Endometriosis and Endometrial Cancer-Association Between Biological Mechanisms and Its Clinical Implications.Journal of clinical medicine · 2026Review
- Article
- Highlighting the molecular refinement of NSMP endometrial cancer in a case of mesonephric-like adenocarcinoma.Gynecologic oncology reports · 2026Article
- Integrated single-cell and bulk transcriptomics reveals an IGF2BP3-driven metabolic circuitry in endometrial cancer.BMC cancer · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) accounts for 90% of uterine cancer cases. It is considered not only one of the most common gynecological malignancies but also one of the most frequent cancers among women overall. Nowadays, the differentiation of EC subtypes is based on immunohistochemistry and molecular techniques. It is considered that patients' prognosis and the implementation of the appropriate treatment depend on the cancer subtype. Patients with pathogenic variants in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.